- Home
- TIL vs INMB Comparison
TIL vs INMB Comparison
Compare TIL & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TIL | INMB |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.4M | 45.7M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | TIL | INMB |
|---|---|---|
| Price | $7.18 | $1.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $125.00 | $5.40 |
| AVG Volume (30 Days) | 10.3K | ★ 707.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.06 | ★ 11.85 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $5.67 | $1.09 |
| 52 Week High | $33.83 | $2.96 |
Technical Indicators
Market Signals| Indicator | TIL | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 50.22 |
| Support Level | $6.85 | $1.21 |
| Resistance Level | $8.30 | $1.76 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 21.05 | 21.62 |
Price Performance
Historical ComparisonAbout TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.